Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder

Behavioural Brain Research

Volumn 207, Issue 1, 2010, Pages 78-83

  Dencker, Ditte ^a   Husum, Henriette ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Amphetamine; Anhedonia; Depression; KCNQ; Lithium; Mania

Indexed keywords

CARBAMAZEPINE; DEXAMPHETAMINE; LAMOTRIGINE; LITHIUM; RETIGABINE; SACCHARIN; VALPROIC ACID;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BIPOLAR DISORDER; BIPOLAR MANIA; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIZATION; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PREDICTIVE VALIDITY; PRIORITY JOURNAL;

AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; ANTIMANIC AGENTS; BEHAVIOR, ANIMAL; BIPOLAR DISORDER; CARBAMATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOOD PREFERENCES; LITHIUM CHLORIDE; MALE; MICE; MOTOR ACTIVITY; PHENYLENEDIAMINES; SACCHARIN; TREATMENT OUTCOME;

EID: 70649099046     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.09.040     Document Type: Article

References (31)

1. + channels in bipolar disorder. Pharmacogenomics J 7 (2007) 123-132
2. Dencker D., Dias R., Pedersen M.L., and Husum H. Effect of the new antiepileptic drug retigabine in a rodent model of mania. Epilepsy Behav 12 (2008) 49-53
3. Goodwin G.M. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17 (2003) 149-173
4. Gribkoff V.K. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets 7 (2003) 737-748
5. Hansen H.H., Andreasen J.T., Weikop P., Mirza N., Scheel-Kruger J., and Mikkelsen J.D. The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. Eur J Pharmacol 570 (2007) 77-88
6. Hansen H.H., Ebbesen C., Mathiesen C., Weikop P., Ronn L.C., Waroux O., et al. The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat. J Pharmacol Exp Ther 318 (2006) 1006-1019
7. Hansen H.H., Waroux O., Seutin V., Jentsch T.J., Aznar S., and Mikkelsen J.D. Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS. J Physiol 586 (2008) 1823-1832
8. Huber M.T., Braun H.A., and Krieg J.C. On the impact of episode sensitization on the course of recurrent affective disorders. J Psychiatr Res 35 (2001) 49-57
9. Kalivas P.W. Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants. Drug Alcohol Depend 37 (1995) 95-100
10. Kessing L.V., Mortensen P.B., and Bolwig T.G. Clinical definitions of sensitisation in affective disorder: a case register study of prevalence and prediction. J Affect Disord 47 (1998) 31-39
11. Kitanaka J., Kitanaka N., and Takemura M. Neurochemical consequences of dysphoric state during amphetamine withdrawal in animal models: a review. Neurochem Res 33 (2008) 204-219
12. Kosten T.R., Markou A., and Koob G.F. Depression and stimulant dependence: neurobiology and pharmacotherapy. J Nerv Ment Dis 186 (1998) 737-745
13. Marken P.A., and Pies R.W. Emerging treatments for bipolar disorder: safety and adverse effect profiles. Ann Pharmacother 40 (2006) 276-285
14. McGregor C., Srisurapanont M., Jittiwutikarn J., Laobhripatr S., Wongtan T., and White J.M. The nature, time course and severity of methamphetamine withdrawal. Addiction 100 (2005) 1320-1329
15. Mikkelsen J.D. The KCNQ channel activator retigabine blocks haloperidol-induced c-Fos expression in the striatum of the rat. Neurosci Lett 362 (2004) 240-243
16. Plosker G.L., and Scott L.J. Retigabine: in partial seizures. CNS Drugs 20 (2006) 601-608
17. Post R.M. Sensitization and kindling perspectives for the course of affective illness: toward a new treatment with the anticonvulsant carbamazepine. Pharmacopsychiatry 23 (1990) 3-17
18. Post R.M. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 149 (1992) 999-1010
19. Robinson T.E., and Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18 (1993) 247-291
20. Rundfeldt C., and Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 50 (2000) 1063-1070
21. Rush A.J., Keller M.B., Bauer M.S., Dunner D., Frank E., and Klein D.F. Diagnostic and statistical manual of mental disorders: DMS-IV. 4th ed. (2000), American Psychiatric Association, Washington, DC pp. 345-428
22. Sax K.W., and Strakowski S.M. Behavioral sensitization in humans. J Addict Dis 20 (2001) 55-65
23. Seiden L.S., Sabol K.E., and Ricaurte G.A. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33 (1993) 639-677
24. Strakowski S.M., and Sax K.W. Progressive behavioral response to repeated d-amphetamine challenge: further evidence for sensitization in humans. Biol Psychiatry 44 (1998) 1171-1177
25. Strakowski S.M., Sax K.W., Setters M.J., Stanton S.P., and Keck P.E. Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: implications for a sensitization model of psychosis in humans. Biol Psychiatry 42 (1997) 749-755
26. Strekalova T., Gorenkova N., Schunk E., Dolgov O., and Bartsch D. Selective effects of citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress. Behav Pharmacol 17 (2006) 271-287
27. Tatulian L., Delmas P., Abogadie F.C., and Brown D.A. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 21 (2001) 5535-5545
28. Tober C., Rostock A., Rundfeldt C., and Bartsch R. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 303 (1996) 163-169
29. Ujike H. Stimulant-induced psychosis and schizophrenia: the role of sensitization. Curr Psychiatry Rep 4 (2002) 177-184
30. Vacca G., Ahn S., and Phillips A.G. Effects of short-term abstinence from escalating doses of d-amphetamine on drug and sucrose-evoked dopamine efflux in the rat nucleus accumbens. Neuropsychopharmacology 32 (2007) 932-939
31. Wickenden A.D., Yu W., Zou A., Jegla T., and Wagoner P.K. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 58 (2000) 591-600